2021 PDA Endotoxins Workshop

Name: 2021 PDA Endotoxins Workshop
Start: 2021-10-07
End: 2021-10-07

Oct 07, 2021

Eastern Standard Time | Online

Virtual

{{Title}} Remove

Online

{{Title}} Remove

Overview
Agenda
Speakers
Additional Information
Registration Fees
Exhibit & Sponsorship
Related Events
Contact

Program Highlights

Now fully virtual! This is the one endotoxins workshop you don’t want to miss. Best part of all is that you can attend from the comfort of your home or office wherever you are!

Overview

On behalf of the Program Planning Committee and PDA, we would like to invite you to the 2021 PDA Endotoxins Workshop on 07 October 2021. The agenda will focus on the theme of “Practical Insights into the Evolution of Endotoxin Testing”.

Endotoxin, a cell wall component of gram negative bacteria, can cause varying levels of immune responses when introduced to the blood system. As a result, the onus is on the manufacturers of all parenteral drugs to control possible endotoxin contamination throughout the manufacturing process. As pharmaceutical manufacturing processes continue to become more streamlined and new therapy delivery continues to evolve, endotoxin control is evolving as well.

The 2021 PDA Endotoxins Workshop will provide scientific understanding and real-world practices for endotoxin testing in bio/pharmaceutical production processes.
Major topics to be covered will include:

Recombinant Reagent
Automation
Data Integrity
The Pyrogenic Dose, Specifications and Co-infusions
Regulatory Compendia

We look forward to seeing you at the 2021 PDA Endotoxins Workshop online!

Agenda

Thursday, 07 October

08:45 – 10:30 | Plenary 1: Recombinant Reagent
Moderator: Anders Thorn, M.Sc. Pharm, Principal Scientist, Microbial Competence Centre, Novo Nordisk A/S

Recombinant reagents for endotoxin detection has been available for many years as an alternate to LAL-based testing and it has been an official method for test for endotoxin in the European Pharmacopeia since January 2021 although comparison of the performance of recombinant reagents and LAL is still subject to discussion.
This session will discuss strategies for validation and for implementation of the recombinant reagents for endotoxins testing. Furthermore, studies that evaluates the use of recombinant technology for the detection of environmental endotoxin will be summarized.

Welcome from the Program Planning Committee Co-Chair

rFC Implementation Strategy for Endotoxin Testing at Sanofi Pasteur
Thierry Bonnevay, Sanofi

Method Validation Strategy for Endotoxin Testing of Water Samples with Recombinant Factor C
Evelyn Der, Genentech

Results and Benefits of using a Novel Recombinant Factor C Assay for Human Tissue Endotoxin Testing
Victoria Rensink, XTANT Medical

Review of Alternatives to Horseshoe Crab Lysates for Endotoxin Testing
Ned Mozier, Pfizer

Q&A Panel Discussion

Break

10:45 – 12:15 | Plenary 2: Automation/Data Integrity
Moderator: Jessica Hankins, Associate Scientific Director, Microbiology Center of Excellence Analytical Strategy and Operations, Bristol Myers Squibb

Automation technologies for bacterial endotoxin testing can improve efficiency and decrease assay variability. This session will focus on providing end-user perspectives when implementing automation technologies in coordination with bacterial endotoxin testing. Vendor representatives will be present for the Question and Answer session to provide additional insights on the various technologies discussed during the session.

Lessons Learned and Benefits Gained from the Global Implementation of an Automated Endotoxin Testing Solution
Phil Duncanson, PhD, Chief Microbiologist, Global Quality, AstraZeneca

End-User Perspective
Mike Knight, Associate Director, QC Microbiology, Genentech

Holy Crab! A Simple, Automated Sample-to-Answer Recombinant Factor C Assay for Bacterial Endotoxins: A Deeper Dive
Benjamin Claywell, Eli Lilly and Company

Q&A Panel Discussion

Josiah Hosie, Lonza
Wilhelm Johnsson, Charles River
Kevin Miller, Hamilton
Kevin Williams, bioMerieux

Lunch

12:30 – 14:00 | Plenary 3: Current Topics in Endotoxin: The Pyrogenic Dose, Specifications and Co-infusions
Moderator: Jay Bolden, Associate Quality Advisor-Biologist, Global Quality Laboratories, Eli Lilly and Company

This session will link the past to the present, and connect theory to patient safety in a clinical setting. The audience will hear the history and development of the threshold pyrogenic dose as it relates to specification setting, and learn about endotoxins and endotoxemia in the area of global patient safety.

TPD, Rabbits/humans, 2X Safety Factor, Real Endotoxin vs. Purified, Impact of FDA-Requested 2X cut
Karen McCullough, Principal Consultant, MMI Associates, LLC

Clinical Relevance of Specification/Co-infusion Impacts to Patient Safety
Doug Roepke, MD, Medical Fellow, GPS Medical - Product Safety Assessment, Eli Lilly & Company

Q&A Panel Discussion

Break

14:15 – 15:45 | Plenary 4: Regulatory Compendia
Moderator: Ingo Spreitzer, PhD, Deputy Head, Microbiological Safety, Paul-Ehrlich-Institut (PEI)

During the last 20 years new methods in the field of Endotoxin/Pyrogen testing have been developed to marketability. The European Pharmacopeia has incorporated these methods in General Chapters, the pharmaceutical industry is asking for global adjustment (harmonization). Hear perspectives from global pharmacopeias and the FDA on the current position towards rFC (MAT), next steps and harmonization.

EDQM – European Pharmacopoeia Approach to Testing for Pyrogenicity
Emmanuelle Charton, PhD, Head of Division B, European Pharmacopoeia Department EDQM

Japanese Pharmacopoeia on rFC
Yutaka Kikuchi, PhD, Expert Committee, Professor, Department of Nutrition, Faculty of Healthcare Sciences Chiba Prefectural University of Health Sciences, Japanese Pharmacopeia

FDA Vision on rFC and MAT
Reyes Candau-Chacon, PhD, Review Microbiologist, Division of Biotechnology Assessment, CDER, U.S. FDA

Q&A Panel Discussion

Highlighted Speakers

Reyes Candau-Chacon

U.S. FDA

Emmanuelle Charton

EDQM

Phil Duncanson

AstraZeneca

Karen Z. McCullough

MMI Associates

Victoria Rensink

Xtant Medical

Kevin L. Williams

bioMerieux

View All

Learning Objectives

Upon completion of this workshop, you will be able to:

Understand complex interaction of endotoxins with immune system
Identify the best test method for endotoxin analysis for your company’s purpose
Select appropriate endotoxin specifications for your company’s products
Describe best practices for your company’s new or existing laboratories

Registration Fees

Registration Type	Regular Registration	Price after 30 September 2021
Member	$837	$1,076
Non-member	$1,033	$1,328
Govern./Health Authority/Academic Member	$392	$504
Govern./Health Authority/Academic Non-member	$448	$576
Student Member	$157	$202
Student Non-member	$174	$223
Early Career Professional Member	$419	$538

Got a Question? We have answers

Exhibitors

Become an Exhibitor

Interested in becoming an exhibitor? Learn about opportunities and benefits.

Request Information

Exhibitor Standard Contract Clause

Attendee List Email Scam

Unfortunately, emails are circulating that offer to sell attendee lists for many of PDA’s conferences and events. These emails are sent by scammers.

Note: PDA does not sell its exhibitor or attendee lists, and no third-party is authorized to distribute or sell any lists related to our events. Statements claiming to offer our attendee lists are fraudulent. If you receive emails that propose to sell PDA conference attendee lists, do not engage with the sender and delete the message immediately.

Media Partners

Related Events

Contact

Program Inquiries

Exhibition Inquiries

Course Inquiries

Registration Customer Care

Tel: +1 (301) 656-5900 ext. 115
[email protected]